CN105243283B - Prostate cancer diagnosis and treatment information acquisition system - Google Patents
Prostate cancer diagnosis and treatment information acquisition system Download PDFInfo
- Publication number
- CN105243283B CN105243283B CN201510752842.7A CN201510752842A CN105243283B CN 105243283 B CN105243283 B CN 105243283B CN 201510752842 A CN201510752842 A CN 201510752842A CN 105243283 B CN105243283 B CN 105243283B
- Authority
- CN
- China
- Prior art keywords
- hsa
- mir
- information acquisition
- prostate cancer
- psa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to a prostate cancer diagnosis and treatment information acquisition system. The invention aims at the screening of prostate cancer by clinical common PSA, the normal range of PSA is more controversial, the risk of prostate cancer of some people is underestimated by taking a simple PSA value, namely, a needle biopsy, and the risk of other people is overestimated. The invention provides a more comprehensive information acquisition system, which comprises the acquisition and statistics of basic medical record information, serum detection information, image analysis information and prostate puncture biopsy information of a prostate cancer patient, so that related indexes of prostate cancer of Chinese people are summarized and measured again, and the indexes suitable for detecting prostate cancer of Chinese people are provided for clinic.
Description
Technical field
The present invention relates to disease information acquisition systems, and in particular to prostate cancer medical information acquisition system, more specifically
It is related to the basic medical record information of patients with prostate cancer, serum detection information, image analysing computer information and aspiration biopsy of prostatic gland information
Acquisition and statistics.
Background technique
Prostate cancer is the entity tumor of the developed countries male disease incidence such as America and Europe highest, the death rate second.In the U.S., about
/ 6th male can be diagnosed as prostate cancer, and there are about 3% chances to die of prostate cancer.China in recent years the disease be in by
Year rise trend, some areas oneself become Patients with Urinary System Tumors the highest malignant tumour of disease incidence.Before clinic is common at present
The screening of column gland specific antigen (PSA) progress prostate cancer.
PSA is mainly by a kind of glycoprotein that prostate epithelial cell generates in the acinus and conduit of prostate, master
It concentrates in prostata tissue, level of the PSA in serum is low-down under normal circumstances.Cause in normal prostatic
Any disease such as prostatic disorders that skin structure destroys, inflammation or wound etc. can cause the PSA in prostata tissue to leak out,
And largely entering blood circulation causes blood-serum P SA to increase.Serum PSA level oneself become many prostatic disorders an important symbol
Object, including benign prostatic hyperplasis, prostatitis, prostate cancer etc..The dispute of PSA normal range (NR) is larger, has Age-specific,
Also there is larger difference between race.
The clinical therapeutic guideline overwhelming majority in terms of China's prostate cancer is all that the data of foreign is actually faced in guidance
Bed work." Chinese urological diseases diagnoses and treatment guide " is mainly according to external data, it is determined that the prostate based on PSA
Aspiration biopsy indication:
1. digital rectal examination finds tubercle, any PSA value；
2.B super generating shows the low echo nodules of prostate or MRI notes abnormalities signal, any PSA value；
3.PSA > 10ng/ml, any f/t PSA and PSAD value；
4.PSA4-l0ng/ml, f/t PSA exception (<0.16) or PSAD value exception (>0.15).
However, prostate cancer, which has, obviously plants group specificity, relies on external data and instruct actually facing for China
Bed work, certainly will will cause apparent deviation.The PSA value for not recommending some simple carries out aspiration biopsy, and individuation is answered to handle,
While considering initial digital rectal examination and PSA, multiple factors are considered as, such as free and t-PSA, age, PSA speed, PSA are close
Degree, family history, race, aspiration biopsy of prostatic gland history and complication.Because simple will lead to using PSA and digital rectal examination
The risk that people suffers from prostate cancer is underestimated, and the risk of another part people is overestimated.
Summary of the invention
For the above problem in current clinic, the present invention provides a kind of prostate cancer medical information acquisition system, including
Patient's essential information acquisition module, blood testing information acquisition module, image information acquisition module and aspiration biopsy information collection
Module, by above-mentioned module collection to information be transmitted to network cloud and summarize, by message processing module to the letter summarized
Breath carries out parameter processing.
Further, patient's essential information acquisition module includes age, household heredity factors, marriage situation, medical history, suction
Cigarette, situations such as drinking.
Further, blood testing information acquisition module includes PSA information acquisition module, ACP information acquisition module and forefront
The novel acquisition module of gland cancer related gene.It is preferred that PSA information acquisition module collects Free PSA, t-PSA, f/t PSA, PSA speed
The information of degree, PSA density.
Blood testing information acquisition module includes all items of conventional blood bio-chemistry checking, preferably includes following items
Detection: Free PSA, t-PSA, f/t PSA, PSA speed, PSA density, serum acid phosphatase (ACP), before more preferably including
The detection of column gland cancer related gene.
Preferably, the relating to prostate cancers is because including one or more of following gene: including miRNA:hsa-
The up-regulation of miR-183, hsa-miR-153 and/or mRNA:SIM2, HPN said gene are positively correlated with prostate cancer risk is suffered from.
It is furthermore preferred that the relating to prostate cancers is because including one or more of following gene: including miRNA:
Hsa-miR-222, hsa-miR-224 and/or mRNA:TCEAL2, CPA6 said gene downward and suffering from prostate cancer risk just
It is related.
Preferably, the relating to prostate cancers is because including one or more of following gene: including miRNA:hsa-
MiR-183, hsa-miR-153, hsa-miR-96, hsa-miR-25, hsa-miR-93 and/or mRNA:SIM2, HPN,
The up-regulation of AMACR, MYC, OR51E2 said gene is positively correlated with prostate cancer risk is suffered from.
Preferably, the relating to prostate cancers is because including one or more of following gene: including miRNA:hsa-
MiR-222, hsa-miR-224, hsa-miR-99b, hsa-miR-221, hsa-miR-204 and/or mRNA:TCEAL2,
The downward of CPA6, C15orf41, VSNL1, KANK1 said gene is positively correlated with prostate cancer risk is suffered from.
Preferably, the relating to prostate cancers is because including one or more of following gene: including miRNA:hsa-
miR-183、hsa-miR-153、hsa-miR-96、hsa-miR-25、hsa-miR-93、hsa-miR-182、hsa-miR-663、
hsa-miR-106b,hsa-miR-130b,hsa-miR-18a；And/or mRNA:SIM2, HPN, AMACR, MYC, OR51E2,
BICD1、DNAH5、PCA3、ARHGEF38、TRIB1、REPS2、GJB1、EPCAM、PCSK6、CAMKK2、STIL、SLC12A8、
GNPNAT1,PVT1,TMTC4；The up-regulation of said gene is positively correlated with prostate cancer risk is suffered from.
Preferably, the relating to prostate cancers is because including one or more of following gene: including miRNA:hsa-
miR-222、hsa-miR-224、hsa-miR-99b、hsa-miR-221、hsa-miR-204、hsa-miR-181c、hsa-miR-
378、hsa-miR-452、hsa-miR-378、hsa-miR-31、hsa-miR-139-5p、hsa-miR-505、hsa-miR-
133a、hsa-miR-328、hsa-miR-27b、hsa-miR-154、hsa-miR-324-5p、hsa-miR-487b、hsa-miR-
502-5p；And/or mRNA:TCEAL2, CPA6, C15orf41, VSNL1, KANK1, NYNRIN, NAV2, ZNF185, STARD5,
GSTP1,ROR2,DUOX1,ALAD,ST5,DBNDD2,SEMA6D,BCL2,DOK4,ST6GALNAC2,ACACB；Said gene
Lower and suffer from prostate cancer risk positive correlation.
Serum acid phosphatase raising is related with prostate cancer transfer, but lacks specificity.In recent years radiommunoassay is used
Its specificity can be improved.Prostatic acid phosphatase monoclonal antibody, prostate antigen measurement its specificity to be improved.The C phase
Prostate cancer 20%~70% has acid phosphatase raising, has lymphatic metastasis also to increase, and has bone certainly if lasting increase
Transfer.Serum acid phosphatase, prostatic acid phosphatase raising person decline after surgery, are that prognosis preferably signifies.It is wrapping
Prostate cancer acid phosphatase in film is secreted by prostatic cell, and through prostate catheter drainage, when prostate cancer, cancer cell is produced
Raw acid phosphatase duct free discharge or conduit are become by carninomatosis to be blocked, enzyme absorbed into serum circulation, so that acid phosphatase increases.
Further, image information acquisition module includes B ultrasound, nuclide bone scan, CT or MRI (magnetic resonance imaging), to above-mentioned
Extraction of Image characteristic parameter.
Current prostate magnetic resonant imaging examination mainly includes routine inspection, as T1 weighted imaging (T1WI) and T2 weight
It is imaged (T2WI), and is capable of providing a variety of fMRIs of functional information, such as Diffusion-Weighted MR Imaging (DWI), dynamic
Enhance image (DCE), magnetic resonance spectrum imaging (MRS) etc..Information between each sequence image can be complementary to one another, but simultaneously
Clinician needs to comprehensively utilize all imaging results, judges to the case where patient, and depends on whether correct judgment
The personal experience of clinician.Computer assisted identification system can effectively avoid doctor based on single index judge, or excessively according to
Rely the subjective judgement in personal experience, multiple parameters can be integrated by computer aided technique and multi-variables analysis is provided, no
Only make the diagnosis process of doctor more objective, and improves diagnosis efficiency.
Preferably, volume parameters of prostate is measured by B ultrasound.Prostate volume be equal to 0.52 multiplied by (left and right, front and back, on
The product of lower three radial line of diameter).
Message processing module respectively believes essential information acquisition module, blood testing information acquisition module and aspiration biopsy
The image feature parameter that the data and image information acquisition module that breath acquisition module obtains are extracted, uses obtained information suitable
Sequence selection method optimizes, and obtains contributing biggish characteristic parameter as prostate cancer Prediction Parameters.
Detailed description of the invention
Fig. 1 prostate cancer medical information acquisition system
Fig. 2 prostate cancer medical information acquisition system detail drawing
Specific embodiment
Present invention will be further explained below with reference to specific examples, for explaining only the invention, and should not be understood as to this
The limitation of invention.It will be understood by those skilled in the art that: without departing from the principle and spirit of the present invention may be used
To carry out a variety of change, modification, replacement and modification to these embodiments, the scope of the present invention is limited by claim and its equivalent
It is fixed.In the following examples, the experimental methods for specific conditions are not specified, usually according to normal condition or according to item proposed by manufacturer
Part examinations.
Embodiment 1
A kind of prostate cancer medical information acquisition system, including patient's essential information acquisition module, blood testing information are adopted
Collect module, image information acquisition module and aspiration biopsy information acquisition module, by above-mentioned module collection to information be transmitted to net
Network cloud is summarized, and carries out parameter processing to the information summarized by message processing module.
Embodiment 2
A kind of prostate cancer medical information acquisition system, including patient's essential information acquisition module, blood testing information are adopted
Collect module, image information acquisition module and aspiration biopsy information acquisition module, by above-mentioned module collection to information be transmitted to net
Network cloud is summarized, and carries out parameter processing, patient's essential information acquisition to the information summarized by message processing module
Module includes age, household heredity factors, marriage situation, situations such as medical history, smoking, drinking.
Embodiment 3
A kind of prostate cancer medical information acquisition system, including patient's essential information acquisition module, blood testing information are adopted
Collect module, image information acquisition module and aspiration biopsy information acquisition module, by above-mentioned module collection to information be transmitted to net
Network cloud is summarized, and carries out parameter processing, the blood testing information collection to the information summarized by message processing module
Module includes all items of conventional blood bio-chemistry checking, specifically may include the detection of following items: Free PSA, total
PSA, f/t PSA, PSA speed, PSA density, serum acid phosphatase (ACP) further may include prostate cancer correlation
Genetic test.
We carry out transcript profile survey by the mRNA and miRNA to 15 patients with prostate cancer and 10 normal healthy controls crowds
Sequence analysis, screens differential expression miRNA and mRNA, wherein 10 in the highly expressed miRNA of prostate cancer group are as follows: hsa-miR-
183、hsa-miR-153、hsa-miR-96、hsa-miR-25、hsa-miR-93、hsa-miR-182、hsa-miR-663、hsa-
miR-106b,hsa-miR-130b,hsa-miR-18a；19 miRNA that expression is lowered are as follows: hsa-miR-222, hsa-
miR-224、hsa-miR-99b、hsa-miR-221、hsa-miR-204、hsa-miR-181c、hsa-miR-378、hsa-miR-
452、hsa-miR-378、hsa-miR-31、hsa-miR-139-5p、hsa-miR-505、hsa-miR-133a、hsa-miR-
328,hsa-miR-27b,hsa-miR-154,hsa-miR-324-5p,hsa-miR-487b,hsa-miR-502-5p；In forefront
20 before the highly expressed mRNA ranking of adenocarcinoma groups are as follows: SIM2, HPN, AMACR, MYC, OR51E2, BICD1, DNAH5, PCA3,
ARHGEF38,TRIB1,REPS2,GJB1,EPCAM,PCSK6,CAMKK2,STIL,SLC12A8,GNPNAT1,PVT1,TMTC4；
20 before the mRNA ranking of prostate cancer group low expression are as follows: TCEAL2, CPA6, C15orf41, VSNL1, KANK1, NYNRIN,
NAV2、ZNF185、STARD5、GSTP1、ROR2、DUOX1、ALAD、ST5、DBNDD2、SEMA6D、BCL2、DOK4、
ST6GALNAC2,ACACB.The differential expression of said gene is all closely related with prostate cancer, can prostate cancer diagnosis the most
Marker.
Embodiment 4
A kind of prostate cancer medical information acquisition system, including patient's essential information acquisition module, blood testing information are adopted
Collect module, image information acquisition module and aspiration biopsy information acquisition module, by above-mentioned module collection to information be transmitted to net
Network cloud is summarized, and carries out parameter processing, the image information acquisition module to the information summarized by message processing module
Including B ultrasound, nuclide bone scan, CT or MRI (magnetic resonance imaging), to above-mentioned Extraction of Image characteristic parameter.
Embodiment 5
A kind of prostate cancer medical information acquisition system, including patient's essential information acquisition module, blood testing information are adopted
Collect module, image information acquisition module and aspiration biopsy information acquisition module, by above-mentioned module collection to information be transmitted to net
Network cloud is summarized, and carries out parameter processing, patient's essential information acquisition to the information summarized by message processing module
Module includes age, household heredity factors, marriage situation, situations such as medical history, smoking, drinking；The blood testing information is adopted
Collection module includes all items of conventional blood bio-chemistry checking, specifically may include the detection of following items: Free PSA, total
PSA, f/t PSA, PSA speed, PSA density, serum acid phosphatase (ACP) further may include prostate cancer correlation
Genetic test；The image information acquisition module includes B ultrasound, nuclide bone scan, CT or MRI (magnetic resonance imaging), to above-mentioned shadow
As extracting characteristic parameter；The relating to prostate cancers is because including one or more of following gene: including miRNA:hsa-
miR-183、hsa-miR-153、hsa-miR-96、hsa-miR-25、hsa-miR-93、hsa-miR-182、hsa-miR-663、
hsa-miR-106b,hsa-miR-130b,hsa-miR-18a；And/or mRNA:SIM2, HPN, AMACR, MYC, OR51E2,
BICD1、DNAH5、PCA3、ARHGEF38、TRIB1、REPS2、GJB1、EPCAM、PCSK6、CAMKK2、STIL、SLC12A8、
GNPNAT1,PVT1,TMTC4；The up-regulation of said gene is positively correlated with prostate cancer risk is suffered from；The relating to prostate cancers because
Including one or more of following gene: including miRNA:hsa-miR-222, hsa-miR-224, hsa-miR-99b, hsa-
miR-221、hsa-miR-204、hsa-miR-181c、hsa-miR-378、hsa-miR-452、hsa-miR-378、hsa-miR-
31、hsa-miR-139-5p、hsa-miR-505、hsa-miR-133a、hsa-miR-328、hsa-miR-27b、hsa-miR-
154,hsa-miR-324-5p,hsa-miR-487b,hsa-miR-502-5p；And/or mRNA:TCEAL2, CPA6,
C15orf41、VSNL1、KANK1、NYNRIN、NAV2、ZNF185、STARD5、GSTP1、ROR2、DUOX1、ALAD、ST5、
DBNDD2,SEMA6D,BCL2,DOK4,ST6GALNAC2,ACACB；The downward of said gene and suffer from prostate cancer risk positive
It closes.
Claims (9)
1. a kind of prostate cancer medical information acquisition system, including patient's essential information acquisition module, blood testing information collection
Module, image information acquisition module and aspiration biopsy information acquisition module, blood testing information acquisition module include that PSA information is adopted
Collect module, ACP information acquisition module and relating to prostate cancers because of information acquisition module, the information that above-mentioned module collection is arrived passes
It is sent to network cloud to be summarized, parameter processing is carried out to the information summarized by message processing module, which is characterized in that described
Relating to prostate cancers because be following miRNA:hsa-miR-183, hsa-miR-153, hsa-miR-96, hsa-miR-25,
hsa-miR-93,hsa-miR-182,hsa-miR-663,hsa-miR-106b,hsa-miR-130b,hsa-miR-18a；With/
Or mRNA:SIM2, HPN, AMACR, MYC, OR51E2, BICD1, DNAH5, PCA3, ARHGEF38, TRIB1, REPS2, GJB1,
EPCAM,PCSK6,CAMKK2,STIL,SLC12A8,GNPNAT1,PVT1,TMTC4；Either following miRNA:hsa-miR-
222、hsa-miR-224、hsa-miR-99b、hsa-miR-221、hsa-miR-204、hsa-miR-181c、hsa-miR-378、
hsa-miR-452、hsa-miR-378、hsa-miR-31、hsa-miR-139-5p、hsa-miR-505、hsa-miR-133a、
hsa-miR-328、hsa-miR-27b、hsa-miR-154、hsa-miR-324-5p、hsa-miR-487b、hsa-miR-502-
5p；And/or mRNA:TCEAL2, CPA6, C15orf41, VSNL1, KANK1, NYNRIN, NAV2, ZNF185, STARD5,
GSTP1,ROR2,DUOX1,ALAD,ST5,DBNDD2,SEMA6D,BCL2,DOK4,ST6GALNAC2,ACACB；Said gene with
Suffer from prostate cancer risk correlation.
2. information acquisition system according to claim 1, which is characterized in that patient's essential information acquisition module includes year
Age, marriage situation, medical history, smokes, situation of drinking at household heredity factors.
3. information acquisition system according to claim 1, which is characterized in that blood testing information acquisition module includes conventional
Blood bio-chemistry checking each project.
4. information acquisition system according to claim 1, which is characterized in that PSA information acquisition module collection Free PSA,
T-PSA, f/t PSA, PSA speed, the information of PSA density.
5. information acquisition system according to claim 1, which is characterized in that image information acquisition module includes B ultrasound, nucleic
Bone scanning, CT or MRI, to the Extraction of Image characteristic parameter of B ultrasound, nuclide bone scan, CT or MRI.
6. information acquisition system according to claim 5, which is characterized in that measure volume parameters of prostate by B ultrasound.
7. information acquisition system according to claim 1, which is characterized in that message processing module makes obtained information
It is optimized with sequential selection method, obtains contributing biggish characteristic parameter as prostate cancer Prediction Parameters.
8. information acquisition system according to claim 1, which is characterized in that the relating to prostate cancers is because being following
MiRNA:hsa-miR-183, hsa-miR-153, hsa-miR-96, hsa-miR-25, hsa-miR-93, hsa-miR-182,
hsa-miR-663,hsa-miR-106b,hsa-miR-130b,hsa-miR-18a；And/or mRNA:SIM2, HPN, AMACR,
MYC、OR51E2、BICD1、DNAH5、PCA3、ARHGEF38、TRIB1、REPS2、GJB1、EPCAM、PCSK6、CAMKK2、
STIL,SLC12A8,GNPNAT1,PVT1,TMTC4；The up-regulation of said gene is positively correlated with prostate cancer risk is suffered from.
9. information acquisition system according to claim 1, which is characterized in that the relating to prostate cancers is because being following
MiRNA:hsa-miR-222, hsa-miR-224, hsa-miR-99b, hsa-miR-221, hsa-miR-204, hsa-miR-
181c、hsa-miR-378、hsa-miR-452、hsa-miR-378、hsa-miR-31、hsa-miR-139-5p、hsa-miR-
505、hsa-miR-133a、hsa-miR-328、hsa-miR-27b、hsa-miR-154、hsa-miR-324-5p、hsa-miR-
487b,hsa-miR-502-5p；And/or mRNA:TCEAL2, CPA6, C15orf41, VSNL1, KANK1, NYNRIN, NAV2,
ZNF185、STARD5、GSTP1、ROR2、DUOX1、ALAD、ST5、DBNDD2、SEMA6D、BCL2、DOK4、ST6GALNAC2、
ACACB；The downward of said gene is positively correlated with prostate cancer risk is suffered from.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510752842.7A CN105243283B (en) | 2015-11-06 | 2015-11-06 | Prostate cancer diagnosis and treatment information acquisition system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510752842.7A CN105243283B (en) | 2015-11-06 | 2015-11-06 | Prostate cancer diagnosis and treatment information acquisition system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105243283A CN105243283A (en) | 2016-01-13 |
| CN105243283B true CN105243283B (en) | 2019-04-19 |
Family
ID=55040930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510752842.7A Active CN105243283B (en) | 2015-11-06 | 2015-11-06 | Prostate cancer diagnosis and treatment information acquisition system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105243283B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105653886B (en) * | 2016-03-25 | 2018-08-14 | 复旦大学附属肿瘤医院 | A kind of prediction aspiration biopsy of prostatic gland suffers from the device of prostate cancer risk |
| CN106778005B (en) * | 2016-12-27 | 2019-06-07 | 中南民族大学 | Prostate cancer computer-aided detection system based on multi-parameter MRI |
| CN107630092B (en) * | 2017-10-23 | 2020-03-31 | 广州医科大学附属第二医院 | Application of miR-505-3p in diagnosis, prognosis and treatment of bone metastasis of prostate cancer |
| CN108206057A (en) * | 2018-03-14 | 2018-06-26 | 苏州大学 | A kind of prostate cancer diagnosis and treatment data platform |
| CN110780074A (en) * | 2019-08-08 | 2020-02-11 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | Kit for detecting integrity of basement membrane of prostate gland and application thereof |
| CN115831362A (en) * | 2022-11-30 | 2023-03-21 | 山东大学齐鲁医院 | Method and system for predicting prostate cancer caused by prostate puncture biopsy |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101137672A (en) * | 2005-02-17 | 2008-03-05 | D·乌尔默特 | Diagnosis of prostate cancer |
| CN104424386A (en) * | 2013-08-23 | 2015-03-18 | 北京大学 | Multi-parameter magnetic resonance image based prostate cancer computer auxiliary identification system |
-
2015
- 2015-11-06 CN CN201510752842.7A patent/CN105243283B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101137672A (en) * | 2005-02-17 | 2008-03-05 | D·乌尔默特 | Diagnosis of prostate cancer |
| CN104424386A (en) * | 2013-08-23 | 2015-03-18 | 北京大学 | Multi-parameter magnetic resonance image based prostate cancer computer auxiliary identification system |
Non-Patent Citations (2)
| Title |
|---|
| 前列腺特异性抗原相关指标在前列腺癌诊断上的应用;莫宏辉等;《华夏医学》;20030831;第16卷(第5期);第765-767页 * |
| 血清PSA值及组织PSA定量相关问题的研究;刘可;《中国博士学位论文全文数据库 医药卫生科技辑》;20111115(第11期);第10-16页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105243283A (en) | 2016-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105243283B (en) | Prostate cancer diagnosis and treatment information acquisition system | |
| CN104372087B (en) | The diagnosing cancer of liver mark being made up of serum microRNA and diagnostic kit | |
| WO2022012284A1 (en) | Peripheral blood tcr marker for melanoma, and detection kit and use thereof | |
| WO2022012292A1 (en) | Peripheral blood tcr marker for pancreatic cancer, and detection kit and use thereof | |
| CN105603101A (en) | Application of system for detecting expression quantity of eight miRNAs in preparation of product for diagnosing or assisting in diagnosing hepatocellular carcinoma | |
| CN108624688A (en) | Applications of the hsa_circ_0012755 as prostate cancer molecular target in preparing drug and kit | |
| CN105154447B (en) | Applications of the AC016745.3 as prostate cancer molecular target and its in diagnostic kit | |
| CN109576370A (en) | Biomarker and detection kit for Diagnosis of Bladder and recurrence monitoring | |
| CN111748629A (en) | Detection reagent of biomarker for early diagnosis of pancreatic cancer | |
| CN109457032A (en) | Thyroid cancer molecule diagnosis kit | |
| CN101792793A (en) | Application of miR-182 as glioma generating molecular marker and detective reagent kit thereof | |
| Park et al. | Factors associated with malignant biliary strictures in patients with atypical or suspicious cells on brush cytology | |
| CN110396545A (en) | A kind of purposes that peripheral circulation blood lncRNA is used to diagnose early primary hepatocarcinoma, prepare primary carcinoma of liver kit for screening | |
| CN105925703A (en) | Method for screening miRNA markers in renal cancer peripheral blood and renal cancer diagnosis marker miR-210 | |
| CN105907875A (en) | Method for screening kidney cancer peripheral blood miRNA marker and kidney cancer marker miR-378 | |
| CN205193799U (en) | Prostate cancer correlation index gathers and statistics module | |
| CN108977511A (en) | Detect the method and application of CST1 gene expression amount in nasal cavity cast-off cells | |
| KR20200015101A (en) | Method for early diagnosis of breast cancer and monitoring after treatment using liquid biopsy multi-cancer gene biomarkers | |
| CN107746888A (en) | LncRNA compositions and the purposes for preparing the diagnosis indication overexpression type Bone of Breast Cancer transfering reagent boxes of Her 2 | |
| CN108728543A (en) | Detect the miRNA combination of brain metastasis and the kit containing the combination | |
| Song et al. | The Value of P504s, 34βE12, Ki-67 and PSA in Diagnosis and Prognosis of Prostate Cancer | |
| CN114045340B (en) | microRNA marker combination for lung cancer diagnosis and application thereof | |
| Shiao et al. | The Relationship between Obesity Indicator and Gallbladder Polyps | |
| JP6865800B2 (en) | Breast cancer evaluation method and urinalysis kit for breast cancer evaluation | |
| Ali Farag et al. | Role of Computed Tomography Perfusion Compared to Computed Tomography Triphasic Study in Assessment of Hepatic Focal Lesions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220526 Address after: 100730 Beijing city Dongcheng District Wangfujing Park No. 1 Patentee after: PEKING UNION MEDICAL COLLEGE Hospital Address before: 100730 Peking Union Medical College Hospital, 1 Shuai Fu Garden, Dongcheng District, Beijing. Patentee before: Wu Zhihong |